The latest news from academia, regulators
research labs and other things of interest
Posted: September 15, 2008
Calando Pharmaceuticals Announces Development of Second siRNA Oncology Therapeutic
(Nanowerk News) Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, announced today that pre-clinical development of a second siRNA oncology therapeutic, CALAA-02, is underway. The intracellular target for CALAA-02 is HIF-2alpha, or Hypoxia Inducible Factor-2 alpha. HIF-2alpha is overexpressed in a number of solid tumors and is critical for many aspects of tumorigenesis, such as metastasis, angiogenesis, tumor cell proliferation, and tumor response to radiation. HIF-2alpha has been difficult to target using traditional drugs but is effectively targeted by the proprietary siRNA in CALAA-02.
“We are encouraged by the results obtained thus far with our proprietary anti-HIF-2alpha siRNA and are excited to pursue pre-clinical development of CALAA-02,” said Calando CSO for siRNA delivery, Jeremy Heidel, Ph.D. “We expect our experience with CALAA-01 will simplify and accelerate CALAA-02 development.”
Calando’s first siRNA therapeutic, CALAA-01, which targets the M2 subunit of ribonucleotide reductase, is currently in a Phase I clinical trial. Calando intends to move CALAA-02 into the clinic in 2009 to demonstrate the ability of the RONDEL™ delivery system to rapidly enable the pathway from target identification through pre-clinical development to clinical application of siRNA therapeutics.
About Calando Pharmaceuticals Inc.
Calando Pharmaceuticals Inc. (www.calandopharma.com), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is a biopharmaceuticals company using proprietary technologies developed at Caltech to create targeted siRNA-based therapeutics and small molecule nanoparticle drug conjugates. Calando uses its innovative Cyclosert™ and RONDEL™ nanoparticle systems to solve the long-standing obstacle of effective delivery and targeting for oligonucleotide and small molecule therapeutics.
Calando’s Cyclosert™ technology uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The Company leverages Cyclosert™ to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics. IT-101 is Calando’s lead small molecule Cyclosert conjugate, which recently completed a phase I study in solid tumors at City of Hope Comprehensive Cancer Center.
Calando’s RONDEL™ technology involves the use of cyclodextrin-containing polymers that form the foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic “backbone” of the siRNA. The polymer and siRNA self-assemble into nanoparticles smaller than 100 nm in diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ligand binds to membrane receptors on the cell surface and the RNA-containing nanoparticle is taken into the cell by endocytosis. There, chemistry built into the polymer functions to unpackage the siRNA from the delivery vehicle. Based upon this breakthrough in siRNA delivery enabled by the RONDEL™ system, the promise of using siRNA in new systemic therapies may finally be realized.